Ampio Pharmaceuticals announced the appointments of Howard Levy, M.B.B.Ch., Ph.D., M.M.M., as Chief Medical Officer (CMO) and J. Kevin Buchi and Michael Martino to the Ampio Pharmaceuticals Board of Directors. Dr. Levy, Mr. Buchi, and Mr. Martino bring extensive experience to Ampio as CEOs, senior executives, and board members of both private and public biopharmaceutical and pharmaceutical companies. Ampio also announced the promotion of Holli Cherevka to the position of President and Chief Operating Officer (COO). Ms. Cherevka has served as Ampio's COO since 2017. Dr. Howard Levy has over 30 years of experience in the pharmaceutical industry, working with both public and private biotechnology companies on clinical and drug development strategy and execution. He was most recently Chief Medical Officer of Catalyst Biosciences, Inc. Prior to that, Dr. Levy was the Senior Global Medical Program Director at CSL Behring; Senior Vice President and Chief Medical Officer at Inspiration Biopharmaceuticals; Chief Medical Officer at Sangart, Inc.; Associate Vice President, Clinical Research, Medical and Regulatory Affairs, at Novo Nordisk; Clinical Research Physician and Medical Director, Acute Care in the U.S.Medical Division of Eli Lilly and Company. He was also Chief of Critical Care Medicine at the University of New Mexico in Albuquerque for 11 years. J. Kevin Buchi is the former President and Chief Executive Officer of Cephalon, Inc., having also served as corporate vice president of global branded products at Teva Pharmaceutical Industries Limited after Teva acquired Cephalon in October, 2011. Mr. Buchi also served as President and Chief Executive Officer of TetraLogic Pharmaceuticals. Mr. Buchi joined Cephalon in 1991 and held various leadership positions during his tenure, including Chief Financial Officer and Chief Operating Officer, before becoming Cephalon's Chief Executive Officer in 2010. In addition, Mr. Buchi currently serves as a Director of Amneal Pharmaceuticals, Inc. and Benitec Biopharma Ltd, as well as Chairman of the Board and Independent Director of Dicerna Pharmaceuticals, Inc. Mr. Buchi previously served on the boards of several pharmaceutical companies, including EPIRUS Biopharmaceuticals, Inc., Alexza Pharmaceuticals, Inc., and Forward Pharma A/S. Michael Martino has extensive experience in the life sciences, spanning a 35-year career. He is currently acting-CEO and Director of HemaFlo Therapeutics, a start-up developing a novel therapy for Acute Kidney Injury, and serves on the board of Caravan Biologix, a start-up developing novel drugs, primarily for oncology. Holli Cherevka has served as Chief Operating Officer of Ampio Pharmaceuticals since 2017. Ms. Cherevka joined Ampio in 2013 as the company's vice president of operations, overseeing clinical, regulatory and manufacturing operations, and all phases of product development.